OptiBiotix Health Appoints New Finance Director to Drive Profitability

OptiBiotix Health ( (GB:OPTI) ) has provided an announcement.

OptiBiotix Health plc has appointed David Blain as the new Finance Director and Company Secretary, effective from January 7, 2025. Blain, who holds extensive experience in finance and board positions across several companies, will support the company’s goal to enhance profitability and establish international brands. This appointment underscores OptiBiotix’s strategy to manage costs and drive revenue growth, positioning it for stronger industry presence and financial performance.

More about OptiBiotix Health

OptiBiotix Health plc is a life sciences company that develops compounds to modify the human microbiome, aiming to prevent and manage diseases such as obesity, cardiovascular health issues, and diabetes. Founded in 2012, OptiBiotix collaborates with over twenty international food and healthcare supplement companies, incorporating its microbiome modulators into various food and drink products. The company also focuses on developing its own range of consumer supplements and health products.

YTD Price Performance: -2.78%

Average Trading Volume: 492,073

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £18.36M

See more data about OPTI stock on TipRanks’ Stock Analysis page.